# Baricitinib in Relapsing Giant Cell Arteritis

> **NCT03026504** · PHASE2 · COMPLETED · sponsor: **Matthew J Koster** · enrollment: 15 (actual)

## Conditions studied

- Arteritis, Giant Cell

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT03026504
- **Lead sponsor:** Matthew J Koster
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-09
- **Primary completion:** 2021-04-12
- **Final completion:** 2021-04-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03026504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03026504, "Baricitinib in Relapsing Giant Cell Arteritis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03026504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*